Navigation Links
NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate
Date:1/12/2010

scope, initiation, rate and progress of its preclinical studies and clinical trials and other research and development activities; animal results may not be predictive of human results; the Company cannot begin any clinical trial until all preclinical testing is completed and the IND is compiled and filed with the FDA; the FDA may request more information or changes to the IND or the clinical plans before human testing may begin; clinical trial results; even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; regulatory approval is needed before any vaccines can be sold in or outside the US; the rate and progress of manufacturing scale-up; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; the company's ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; the company's ability to enter into future collaborations with industry partners and the terms, timing and success of any such collaboration; the cost, timing and success of regulatory filings and approvals; the company's ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and the availability of qualified personnel.  Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at '/>"/>
SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, a designer ... & Marketing Director. , With more than 25 years of experience in ... Tronics’ business development activities worldwide. He brings to the company his strong expertise ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
(Date:7/30/2015)...  With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness ... more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In ... Headquartered in Dallas, TX , ISN has additional ...
(Date:7/30/2015)... July 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... received the second $1.0M tranche under a previously ... grant valued at up to $3.0 million to ... surfactant as a potential medical countermeasure to mitigate ... was awarded an initial $1.0 million under this ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... 1, 2010 Amgen (Nasdaq: AMGN ) Senior ... will urge members of a U.S. Food and Drug Administration ... establish approval standards that ensure patient safety and follow a ... will follow," Dr. Miletich said.  "Amgen believes biosimilars have a ...
... PharmaNet Development Group, Inc., a leading provider of ... medical device companies, today announced its experts will share ... Annual Partnerships in Clinical Trials Conference taking place from ... At the conference, members of PharmaNet,s management ...
... BOSTON, Oct. 30 Tibotec Pharmaceuticals (Tibotec) announced today the ... analysis of the phase 2 response-guided PILLAR study in treatment-naive ... the 61st Annual Meeting of the American Association for the ... data will be presented as part of a late-breaker oral ...
Cached Biology Technology:Amgen to Provide Testimony at FDA Hearing on Biosimilars 2Amgen to Provide Testimony at FDA Hearing on Biosimilars 3Amgen to Provide Testimony at FDA Hearing on Biosimilars 4PharmaNet Development Group Experts to Share Insights at the 9th Annual Partnerships in Clinical Trials Conference in Vienna 2Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD 2Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD 3Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD 4
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. ... molecular diagnostics, today announced the launch of a ... Company,s Precision Cancer Monitoring℠ (PCM) technology for predicting ... one or a combination of the novel immunotherapy ... (nivolumab), a PD-1 inhibitor. The 50-patient study will ...
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
(Date:7/7/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... commerce market announces a revised version of one of its first ... air on CNBC in New York , ... San Francisco metro areas.    ... ability to replace all the cards in your wallet and keep ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... Meteosat in 1977, 33 years of imagery combined with ... improve weather forecasting, with direct benefits for us. ... satellites, like Meteosat Second Generation (MSG). Today, thousands of ... use of the world,s most powerful computers. The MSG ...
... and the functions and properties of tissues and organs ... clusters have not been examined in great detail. ... Systems (EBICS) Center to be operated by the Massachusetts ... Urbana-Champaign, and the Georgia Institute of Technology intends to ...
... An extremely small RNA molecule created by a University of ... to synthesize proteins, the building blocks of life. The findings ... of Earthly life," the lead researcher contends. The ... reaction is described in a paper published this week in ...
Cached Biology News:$25M NSF center established to investigate the creation of biological machines 2$25M NSF center established to investigate the creation of biological machines 3$25M NSF center established to investigate the creation of biological machines 4U. of Colorado scientists create tiny RNA molecule with big implications for life's origins 2U. of Colorado scientists create tiny RNA molecule with big implications for life's origins 3
... an enzyme that catalyzes the hydrolysis ... maltotriose, and dextrins. The,level of a-amylase ... body is of,clinical significance in the ... diabetes; plant and microbial a-amylases are,important ...
Rat monoclonal [20d5] to NKG2A + C+ E ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Mouse): CHO transfected cells expressing the B6 allele of NKG2A. Entrez Gen...
... Labsystems Wellmix is a high-quality four-place microplate ... The shaking speed is adjustable from 100 ... speed and a small orbit ensure effective ... time is quick and easy to set ...
... Ascent FL is equipped ... luminometric measurement technologies that ... of advanced features of ... Ascent. Fluoroskan Ascent FL ...
Biology Products: